JankowskiJA, OdzeRD. Biomarkers in gastroenterology: between hope and hype comes histopathology. Am J Gastro-enterol.2009; 104: 1093–1096.
2.
FigueiredoC, van DoornLJ, NogueiraC. Helicobacter pylori genotypes are associated with clinical outcome in Portuguese patients and reveal a high prevalence of infections with multiple strains. Scand J Gastroenterol.2001; 36: 128–135.
3.
MachadoJC, PharoahP, SousaS. Interleukin-1b and inter-leukin-1 receptor antagonist gene polymorphisms are associated with increased risk of gastric carcinoma. Gastroenterology.2001; 121: 823–829.
4.
FigueiredoC, MachadoJC, PharoahP. Helicobacter pylori and interleukin-1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma?J Natl Cancer Inst.2002; 94: 1680–1687.
5.
MachadoJC, FigueiredoC, CanedoP. A pro-inflammatory genetic profile increases the risk of chronic atrophic gastritis and gastric carcinoma. Gastroenterology.2003; 125: 364–371.
VarisA, ZaikaA, PuolakkainenP. Coamplified and over-expressed genes at ERBB2 locus in gastric cancer. Int J Cancer.2004; 109: 548–553.
8.
ParkDI, YunJW, ParkJH. HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci.2006; 51: 1371–1379.
9.
KimMA, JungEJ, LeeHS. Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction. Hum Pathol.2007; 38: 1386–1393.
10.
Barros-SilvaJD, LeitãoD, AfonsoL. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer.2009; 100: 487–493.
11.
DavidL, SerucaR, NeslandJM. c-erbB-2 Expression in primary gastric carcinomas and their metastases. Mod Pathol.1992; 5: 384–390.
12.
Van CutsemE, KangY, ChungH. Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J Clin Oncol.2009; 27: 18.
13.
CarneiroF, OliveiraC, LeiteM, SerucaR. Molecular targets and biological modifiers in gastric cancer. Semin Diagn Pathol.2008; 25: 274–287.
14.
PintoM, WuY, MensinkRG, CirnesL, SerucaR, HofstraRM. Somatic mutations in mismatch repair genes in sporadic gastric carcinomas are not a cause but a consequence of the mutator phenotype. Cancer Genet Cytogenet.2008; 180: 110–114.
15.
WuCW, ChenGD, JiangKC. A genome-wide study of microsatellite instability in advanced gastric carcinoma. Cancer.2001; 92: 92–101.
16.
BeghelliS, de ManzoniG, BarbiS. Microsatellite instability in gastric cancer is associated with better prognosis in only stage II cancers. Surgery.2006; 139: 347–356.
17.
LindorNM, RabeK, PetersenGM. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA2005; 293: 1979–1985.
18.
Al-TassanN, ChmielNH, MaynardJ. Inherited variants of MYH associated with somatic G:C>T:A mutations in colorectal tumors. Nat Genet.2002; 30: 227–232.
19.
BolandCR. Evolution of the nomenclature for the hereditary colorectal cancer syndromes. Fam Cancer.2005; 4: 211–218.
20.
LigtenbergMJ, KuiperRP, ChanTL. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3, exons of TACSTD1. Nat Genet.2009; 41: 112–117.
21.
HitchinsMP, WongJJ, SuthersG. Inheritance of a cancer-associated MLH1 germ-line epimutation. N Engl J Med.2007; 356: 697–705.
22.
SayedMG, AhmedAF, RingoldJR. Germline SMAD4 or BMPR1A mutations and phenotype of juvenile polyposis. Ann Surg Oncol.2002; 9: 901–906.
23.
LuSL, KawabataM, ImamuraT. HNPCC associated with germline mutation in the TGF-beta type II receptor gene. Nat Genet.1998; 19: 17–18.
24.
LammiL, ArteS, SomerM. Mutations in AXIN2 cause familial tooth agenesis and predispose to colorectal cancer. Am J Hum Genet.2004; 74: 1043–1050.
25.
JassJR, CottierDS, PokosV, ParryS, WinshipIM. Mixed epithelial polyps in association with hereditary non-polyposis colorectal cancer providing an alternative pathway of cancer histogenesis. Pathology.1997; 29: 28–33.
26.
YoungJ, BarkerMA, SimmsLA. Evidence for BRAF mutation and variable levels of microsatellite instability in a syndrome of familial colorectal cancer. Clin Gastroenterol Hepatol.2005; 3: 254–263.
27.
CheahPY, WongYH, ChauYP. Germline bone morphogenesis protein receptor 1A mutation causes colorectal tumorigenesis in hereditary mixed polyposis syndrome. Am J Gastroenterol.2009; 104: 3027–3033.
28.
van KriekenJH, JungA, KirchnerT. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for a European quality assurance program. Virchows Arch.2008; 453: 417–431.
